Ontology highlight
ABSTRACT:
SUBMITTER: Gallant J
PROVIDER: S-EPMC5172523 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature
Gallant Joel J Brunetta Jason J Crofoot Gordon G Benson Paul P Mills Anthony A Brinson Cynthia C Oka Shinichi S Cheng Andrew A Garner Will W Fordyce Marshall M Das Moupali M McCallister Scott S
Journal of acquired immune deficiency syndromes (1999) 20161101 3
Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-label, noncomparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/hepatitis B virus (HBV)-coinfected adults. At 48 weeks, 91.7% of the 72 participants maintained or achieved viro ...[more]